There has been encouraging news from a PhaseThe different stages of clinical trials that must be done to investigate a new drug. Phase 1 is the first stage while phase 4 is the final stage. III clinical trial investigating a new treatment for people with relapsed or refractory osteosarcoma.
What is the treatment?
The treatment, called Ris-Rez (risvutatug rezetecan), is a type of targeted therapy known as an antibody-drug conjugate (ADC).
Unlike traditional chemotherapy, which affects both healthy and cancer cells, an ADC is designed to recognise a specific marker found on cancer cells called B7-H3. Once attached, it delivers chemotherapy directly into those cells, with the aim of improving effectiveness while limiting damage to healthy tissue.
Who took part in the trial?
The Phase III ARTEMIS-011 study enrolled patients in China with relapsed or refractory osteosarcoma. These were patients whose cancer had returned or continued to grow despite receiving at least two previous lines of treatment.
For people in this situation, treatment options are currently very limited, making research into new therapies especially important.
What did the company announce?
According to the company’s announcement, the trial met its primary endpoint, meaning patients receiving Ris-Rez experienced a longer period before their cancer progressed compared with those receiving standard chemotherapy.
This measurement is called progression-free survival (PFS).
In simple terms, progression-free survival measures how long a treatment can keep the cancer under control before it starts growing again. It does not necessarily mean the cancer has been cured or that patients lived longer.
The company also reported encouraging results for overall survival, which measures how long patients live after starting treatment. However, the detailed survival data have not yet been released, so it is not yet known how much longer patients lived or whether the improvement is considered clinically significant.
Why should we be cautious?
At this stage, only a summary of the results has been published in a company press release. Important information is still missing, including:
- The exact improvement in progression-free survival.
- How many months overall survival improved.
- The percentage of patients whose tumours responded to treatment.
- Which groups of patients benefited the most.
- Detailed information about side effects and quality of life.
These details are typically shared later at international medical conferences and in peer-reviewed scientific journals, where independent experts can carefully review the findings.
Is this still good news?
Yes. Positive Phase III trials in osteosarcoma are uncommon, particularly for patients whose disease has returned after treatment. Reaching the primary goal of a Phase III study is therefore an encouraging milestone.
The treatment also represents a different approach to treating osteosarcoma. Rather than relying solely on traditional chemotherapy, it uses targeted technology designed to deliver treatment directly to cancer cells. If future analyses confirm these early findings, it could represent an important step forward for patients with relapsed disease.
However, it is important to balance optimism with realism. Until the complete data are available, it is not possible to fully understand how large the benefit is or whether the treatment should become a new standard of care.
What happens next?
The full trial results are expected to be presented at an international scientific meeting and published in a peer-reviewed medical journal. This will allow independent experts to examine the data in detail.
Regulatory authorities will also review the complete evidence before deciding whether the treatment should be approved for use.
Meanwhile, researchers continue to study Ris-Rez in international clinical trials to better understand its role in treating osteosarcoma and other sarcomas.
Our view
At Osteosarcoma Now, we welcome every positive step forward in osteosarcoma research while recognising the importance of robust scientific evidence.
The announcement from the ARTEMIS-011 trial is encouraging and offers hope for people affected by relapsed osteosarcoma. However, these are preliminary company-reported results, and important questions remain unanswered until the full data are published and independently reviewed.
Key Takeaways
- Encouraging news: A Phase III clinical trial of a new targeted treatment for relapsed osteosarcoma has met its main goal.
- The full picture isn’t available yet: The results have been announced by the company developing the treatment, but the complete scientific data have not yet been published or independently reviewed.
- More information is needed: We are waiting for the detailed results, peer-reviewed publication and regulatory review to understand exactly how much benefit the treatment may provide.
- We will continue to follow this story closely and provide updates as more evidence becomes available, helping patients, families and healthcare professionals understand what these developments may mean in practice.
Reference https://www.cancernetwork.com/view/ris-rez-hits-pfs-end-point-in-phase-3-osteosarcoma-trial